AgingResearch.NewsJoin free

Phase 3Completed

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

Sponsor
Alcon Research (Industry)
Enrolment
221 enrolled
Conditions
Ocular Inflammation Associated With Blepharaconjunctivitis
Interventions
Tobramycin 0.3%/Dexamethasone 0.05%; TOBRADEX
Ages
children, adults, older adults
Registry
NCT00576251

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis

Primary outcomes

  • Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4)

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started